The $15 price target has become a widely cited objective for Alpha Tau Medical Ltd. (DRTS), a clinical-stage oncology company developing its proprietary Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) technology. HC Wainwright has reiterated its Buy rating and $15 target on multiple occasions throughout 2026, most recently in July. Barclays went further, raising its target from $15 to $17 in June while maintaining an Overweight rating. Ladenburg Thalmann raised its target to $14. Market participants have gravitated toward $15 as a consensus milestone because it sits above the stock's 52-week high of $14.11 and represents a psychologically significant round number that, if breached, would confirm a major breakout.
The biggest potential catalyst is the ReSTART pivotal trial, which completed enrollment of 88 patients across the United States, Israel, and Canada. This study evaluates Alpha DaRT in recurrent cutaneous squamous cell carcinoma, and topline data are expected around the end of 2026. Positive results would support the company's ongoing modular Premarket Approval (PMA) submission to the U.S. Food and Drug Administration (FDA), with Barclays projecting potential regulatory approval in 2027.
Separately, the REGAIN trial in recurrent glioblastoma has already generated significant enthusiasm. Interim data showed that two out of three patients achieved a complete response—tumor lesions disappeared entirely on MRI scans—while the third patient demonstrated stable disease with a 30% tumor size reduction. All three patients achieved 100% local disease control. The FDA subsequently cleared the company to resume enrollment of the final seven patients and authorized two additional academic cancer centers to join the trial. Alpha DaRT holds Breakthrough Device designation for this indication.
Additional pipeline breadth adds upside optionality. Clinical programs span pancreatic cancer, head and neck squamous cell carcinoma, liver cancer, and breast cancer. Because Alpha DaRT is not a targeted therapeutic requiring a specific biomarker, the technology is potentially tumor-agnostic—a feature that significantly expands the total addressable market if clinical validation continues.
Alpha Tau Medical remains a pre-revenue company with no approved commercial products. In its most recent quarter, the company reported a net loss of $22.9 million, or $0.26 per share, which missed consensus estimates by $0.13. Operating losses are expected to continue as clinical programs advance, with analysts forecasting full-year EPS of approximately -$0.67.
Cash reserves stood at $80 million at the end of the first quarter, providing a runway into 2027 according to company commentary. However, without revenue, the company remains dependent on capital markets or partnership deals to fund operations. Any delay in clinical timelines, disappointing trial data, or an unfavorable FDA review could trigger sharp downside, especially given the stock's beta of 1.17 and a 52-week range that stretches from $2.87 to $14.11.
Analyst sentiment is also divided. While HC Wainwright, Barclays, Ladenburg Thalmann, and Citi maintain Buy-equivalent ratings, Piper Sandler holds a Neutral rating with an $8 target, and Zacks Research downgraded the stock to Strong Sell in July. Weiss Ratings assigned a Sell rating earlier in the year. This split reflects genuine uncertainty about execution risk and valuation after a year-to-date rally of more than 138% and a one-year surge exceeding 280%.
Among five analysts tracked by S&P Global, the average 12-month price target is $14.20, implying roughly 20% upside from recent levels. The high target is $17.00 (Barclays) and the low is $8.00 (Piper Sandler). MarketBeat's broader survey of seven analysts produces a consensus Hold rating and an average target of $12.60. The divergence between the bullish and cautious camps underscores that $15 is achievable but by no means guaranteed—it sits squarely between the average and the high end of Wall Street's range.
From a technical perspective, the $15 target lies just above the stock's 52-week high of $14.11, making that prior peak a formidable resistance level. Before $15 comes into play, DRTS must first reclaim and hold above $14.11. The 50-day simple moving average, recently near $10.96, and the 200-day moving average near $8.57, define the underlying trend structure. As long as the stock trades above both moving averages, the intermediate-term trend favors buyers. A failure to hold the $10.50–$11.00 zone, however, would raise questions about momentum. The wide 52-week range—from $2.87 to $14.11—reflects the stock's volatile, catalyst-driven nature common among clinical-stage biotech names.
Traders and investors navigating volatile clinical-stage stocks like Alpha Tau Medical can benefit from systematic, data-driven tools that reduce emotional bias. Tickeron's AI Daily Buy/Sell Signals leverage artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals in response to shifting technical patterns, market conditions, and AI-driven analysis. Rather than manually scanning charts and news feeds, users can rely on these signals to identify emerging opportunities, track positions with greater discipline, and stay ahead of trend changes across the market. For those looking to navigate fast-moving equities more efficiently, exploring AI-powered signal tools can offer a meaningful edge.
The path to $15 for Alpha Tau Medical is plausible and supported by tangible catalysts: pivotal ReSTART data expected by year-end, encouraging early glioblastoma results, an active FDA submission process, and endorsement from several prominent analyst desks. The stock's powerful rally over the past year reflects genuine progress in the clinic and growing recognition of Alpha DaRT's potential across multiple solid tumor types. However, the journey from $11.79 to $15—and beyond—requires flawless execution. Any stumble in trial results, regulatory setbacks, or financing difficulties could quickly reverse hard-won gains. Investors should monitor ReSTART data readouts, FDA submission updates, cash burn rates, and the stock's ability to clear the $14.11 resistance level as the most important signposts on the road to $15.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, DRTS has been loosely correlated with ORMP. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if DRTS jumps, then ORMP could also see price increases.
| Ticker / NAME | Correlation To DRTS | 1D Price Change % | ||
|---|---|---|---|---|
| DRTS | 100% | -1.72% | ||
| ORMP - DRTS | 48% Loosely correlated | +2.28% | ||
| ABCL - DRTS | 28% Poorly correlated | +3.74% | ||
| IBIO - DRTS | 27% Poorly correlated | +2.14% | ||
| RXRX - DRTS | 27% Poorly correlated | -4.53% | ||
| JAGX - DRTS | 27% Poorly correlated | +16.97% | ||
More | ||||